Weight Loss Drugs
42 articles on Weight Loss Drugs, written by Shotlee and medically reviewed for clinical accuracy.
Eli Lilly Eyes India Rollout for Oral Obesity Drug Orforglipron
US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.
5 min read
Untold Dangers of GLP-1s: Ozempic, Wegovy & Mounjaro Risks
Wegovy, Ozempic, and Mounjaro promise effortless weight loss with minimal risk, but new research uncovers deeper dangers like altered brain chemistry and loss of desire. On The Spectacle Podcast, Scott McKay and Melissa Mackenzie dive into the science, Melissa's personal story, and why lifestyle changes offer a safer path.
5 min read
Entrepreneur Uses AI to Build $1B Telehealth Company on GLP-1 Drugs
Matthew Gallagher, a 41-year-old LA entrepreneur, turned $20,000 into a nearly $2 billion telehealth empire with AI alone. Medvi sells GLP-1 drugs like Ozempic at $300 versus $1,000 retail, serving 250,000 customers. But rapid growth sparks debates on legality and fake ads.
5 min read
Man Wanted for Stealing £12k Mounjaro After Court No-Show
A 27-year-old man from Wigan is being hunted by police after failing to appear in court on charges of stealing over £12,000 worth of Mounjaro weight loss injections from his workplace. The theft highlights the skyrocketing demand for this GLP-1 medication used for type 2 diabetes and appetite control. Understand the case details and what makes Mounjaro so sought after.
4 min read
Emcure Halves Poviztra Semaglutide Price After Novo Nordisk Patent Expiry
Emcure Pharmaceuticals has halved the price of its semaglutide-based weight loss drug Poviztra after the expiry of Novo Nordisk's patent, making GLP-1 therapy more accessible. Originally developed for diabetes, semaglutide mimics hormones to control appetite and blood sugar, delivering unmatched weight loss results. Check the new rates and learn what this means for patients seeking effective metabolic treatments.
4 min read
FDA Approves Eli Lilly's Foundayo GLP-1 Pill, Stock Jumps 5%
Eli Lilly's shares surged more than 5% following FDA approval of Foundayo, its new once-daily GLP-1 weight-loss pill that can be taken anytime without food restrictions. This oral option intensifies competition with Novo Nordisk's Wegovy and Ozempic, offering real-world convenience for overweight adults. Discover the trial results, comparisons, and implications for obesity treatment.
4 min read
'Ozempic Teeth': Dentists Urge Awareness of Weight Loss Drug Oral Risks
Weight loss drugs like Ozempic are transforming bodies, but dentists are sounding the alarm on 'Ozempic teeth'—a pattern of dry mouth, tooth sensitivity, and gum problems. Lt. Gen Dr Vimal Arora of Clove Dental notes increased xerostomia, dental caries, and early periodontal inflammation among users. Discover why this happens and steps to safeguard your smile.
4 min read
Telangana Warns on Semaglutide Misuse for Weight Loss
Telangana's Drugs Control Administration has issued a stark warning against misusing Semaglutide formulations for weight loss without medical oversight. With patent expiry looming in March 2026, multiple versions are flooding the market, raising safety concerns. Improper use risks serious complications like pancreatitis and gastrointestinal disorders.
5 min read
DCGI Intensifies Crackdown on Unauthorized GLP-1 Weight-Loss Drug Sales
India's DCGI is cracking down harder on the unauthorized sale of GLP-1 weight-loss drugs amid rising generic variants. Inspections at online pharmacies, wholesalers, and clinics aim to prevent misuse that could lead to serious health risks. Patients must seek prescriptions only from qualified endocrinologists or specialists.
4 min read
Ozempic Lightens Truckers' Loads: GLP-1 Cuts Food Freight
GLP-1 medications like Ozempic are reshaping America's waistlines—and its freight lanes. With 12% of U.S. adults adopting these appetite-suppressing drugs, food demand is down 3%, slashing millions of truckloads from snacks, beverages, and more. This public health trend is quietly disrupting the trucking industry.
6 min read
Semaglutide Generics Set for One-Fourth Price After Patent Expiry
Semaglutide prices in India are poised for a dramatic drop to one-fourth of current levels following patent expiry on March 20. Generics from seven companies like Sun Pharma and Zydus Lifesciences will make Ozempic and Wegovy alternatives more accessible for diabetes and obesity management. Experts highlight improved adherence but warn of misuse risks.
5 min read
When Weight-Loss Drugs Like Zepbound Don't Work
Jessica Layeux spent 15 months on Zepbound with minimal weight loss, joining 1 in 10 clinical trial non-responders who lose less than 5% body weight. Scientists are investigating genetics, hormones, and other factors behind why these popular GLP-1 drugs don't work for everyone. This guide explains the science and next steps for patients.
5 min read
India GLP-1 Weight-Loss Drug Market to Reach ₹5,000 Crore by 2030: CareEdge
India's GLP-1 and weight-loss drug market is set for explosive growth, expanding fivefold to ₹5,000 crore by 2030, according to CareEdge Ratings. Semaglutide's patent expiry will trigger sharp price cuts, boosting access amid surging demand from type 2 diabetes patients. However, generic makers face patent battles, manufacturing hurdles, and safety scrutiny.
5 min read
GLP-1 Discontinuation: Mixed Weight Loss Results in Real-World Study
A large real-world study from Cleveland Clinic reveals mixed outcomes after GLP-1 discontinuation: 55% of obese patients regained weight, while 45% maintained or continued losing. Many switched to alternative treatments, highlighting the need for ongoing obesity care. This data underscores gaps in long-term management and the role of nutritional support.
5 min read
Brianna LaPaglia's Ozempic Warning: 3 Pressures Behind Viral Claim
Influencer Brianna 'Chickenfry' LaPaglia's TikTok blast—'You're gonna die. You're all gonna die.'—targets Ozempic use among those who 'do not need' it, sparking viral debate. Page Six coverage highlights three colliding pressures amid Baptist Health's side effect warnings. Her personal recovery from disordered eating adds weight to the caution.
5 min read
Aspen Plans Mounjaro Rollout in Sub-Saharan Africa
South Africa's Aspen Pharmacare is accelerating Mounjaro's rollout across sub-Saharan Africa after its explosive success at home, where the GLP-1 market tripled to $133.6 million. With over half the market share and $78.97 million in projected sales, this expansion tests rapid access to advanced weight-loss therapies. Here's how Aspen's KwikPen approval paves the way.
4 min read
Ireland's Each-Way Bet on Wegovy and Mounjaro Rivals
A spectacular backfire in Novo Nordisk's head-to-head trial against Eli Lilly's Mounjaro has widened the gap in the weight loss drug race, yet Ireland stands to gain from both giants. With billions in investments, thousands of jobs, and massive tax revenues, the Republic is placing an each-way bet on Wegovy and Mounjaro. This economic tie underscores pharma's pivotal role in Ireland's prosperity.
6 min read
Novo's Woes Despite Ozempic's Explosive Growth
Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.
5 min read
Viking Therapeutics Shares Surge 12% as Novo's CagriSema Stumbles
Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.
5 min read
CagriSema Falls Short vs. Tirzepatide in Obesity Drug Trial
In a pivotal head-to-head trial, Novo Nordisk's next-generation obesity drug CagriSema delivered 23% body weight reduction over 84 weeks, missing the mark against Eli Lilly's tirzepatide at 25.5%. This setback highlights the intense competition in the weight-loss market. Novo shares dropped 11%, while Lilly's rose 4%.
5 min read
Semaglutide Nasal Spray: Affordable Weight Loss Option Coming Soon
A nasal spray version of semaglutide, the active ingredient in Ozempic and Wegovy, could soon offer an affordable alternative for weight loss. Chinese firm Shanghai Shiling Pharmaceutical is advancing trials, aiming for global markets by 2028 amid soaring demand. This development aligns with Novo Nordisk's upcoming patent loss in China, paving the way for cheaper generics.
5 min read
Meijer Reduces Out-of-Pocket Costs for GLP-1 Meds Like Ozempic, Wegovy
Meijer is making GLP-1 medications more affordable by accepting manufacturer savings programs for Ozempic and Wegovy, dropping costs to $199 per month for the first two months on lowest doses. The retailer also offers the newly approved oral Wegovy through the same program, starting at $149 out-of-pocket. This move aims to boost access to these popular weight loss injections amid rising demand.
5 min read
Weight-Loss Price Wars Upend Big Pharma's Model
Two years ago, GLP-1 prescriptions cost over $1,000 monthly for uninsured patients. Now, Wegovy's pill starts at $149, flipping Big Pharma's playbook amid fierce price wars. As Novo Nordisk forecasts sales drops and Eli Lilly surges, discover how consumer demand is reshaping obesity treatments.
6 min read
Super Bowl LX Ads Feature AI, Weight-Loss Drugs & Celebs
Super Bowl LX ads are packed with celebrities from Kendall Jenner to George Clooney, cutting-edge AI demos, and a surge in health spots promoting GLP-1 weight-loss drugs like Ozempic and Wegovy. As viewership hits record highs, advertisers are betting big on telehealth and pharma amid booming demand. This preview reveals the trends shaping America's biggest ad showdown.
6 min read
Unexpected Ozempic, Wegovy & Mounjaro Side Effects: Real Stories
GLP-1 drugs like Ozempic and Mounjaro promise transformative weight loss and blood sugar control, but real users reveal side effects beyond the label. From severe nausea and hair loss to surprising benefits like reduced OCD, these stories highlight the need for informed use. Learn the science, risks, and tips to manage them effectively.
5 min read
GLP-1 Kidney Risks: Study Compares Ozempic to SGLT2 Drugs
A recent Danish study in JAMA Internal Medicine highlights higher kidney risks with popular GLP-1 drugs like Ozempic compared to SGLT2 inhibitors. While GLP-1s offer weight loss benefits, understanding these findings is crucial for patients. Learn the science, risks, and how to protect your kidneys.
5 min read
Medicare GLP-1 Coverage 2026: Wegovy, Zepbound Guide
Medicare is breaking its long-standing rule against covering weight loss drugs like Wegovy and Zepbound through a new GLP-1 initiative. Starting with a bridge phase in July 2026, eligible beneficiaries could pay just $50 monthly copays—if they act now. This guide explains the changes, requirements, and clinical context for GLP-1 therapy.
4 min read
Roche CT-388: 22.5% Weight Loss Tops Wegovy in Phase 2 Trial
Roche's experimental obesity drug CT-388 delivered impressive 22.5% average weight loss in a phase 2 trial, surpassing Novo Nordisk's Wegovy and rivaling Eli Lilly's Zepbound. Over half of participants resolved obesity by dropping below a BMI of 30. This positions Roche as a serious contender in the booming GLP-1 market.
4 min read
WHO's Shift: GLP-1 Drugs Transform Obesity Treatment
The WHO has issued landmark guidelines endorsing GLP-1 receptor agonists for obesity treatment, marking a pivotal shift from lifestyle-only approaches. These drugs, including semaglutide and tirzepatide, offer substantial weight loss but come with cautions on long-term safety. This guide unpacks the science, evidence, and practical implications for patients.
4 min read
Higher-Dose Wegovy: NHS Trials, Real Results & Safety
The NHS has approved a triple-strength 7.2mg Wegovy dose, promising greater weight loss for those plateauing on standard semaglutide. One user's story highlights the frustration of switching from Mounjaro due to costs, sparking debate on higher GLP-1 doses. Discover the science, safety, and what it means for metabolic health.
5 min read
Counterfeit GLP-1 Pills: Risks and How to Stay Safe
Demand for GLP-1 weight loss medications is soaring, but the shift to easier-to-fake oral pills spells trouble. Counterfeit versions pose serious health risks, from incorrect dosing to contamination. This guide explains the threats and equips you with strategies to stay safe.
4 min read
Oral GLP-1s: Orforglipron vs. Oral Wegovy Explained
The race for oral GLP-1 medications is intensifying, with Novo Nordisk's oral Wegovy now approved and Eli Lilly's orforglipron facing a brief FDA review extension. These pill-based alternatives to injections promise easier access for weight loss and metabolic health. Learn how they stack up in efficacy, tolerability, and real-world impact.
4 min read
Generic Ozempic & Wegovy in India: Patient Guide
Generic versions of blockbuster GLP-1 drugs Ozempic and Wegovy are now approved in India, promising lower costs and wider access. Patients can expect semaglutide generics from Sun Pharma, Zydus Lifesciences, and others amid patent expiry in 2026. This guide breaks down the science, benefits, and key considerations for safe use.
4 min read
Retatrutide Explained: Triple Agonist Weight Loss Drug
Retatrutide is exploding on TikTok among gym enthusiasts for its potent weight loss effects, but it's not FDA-approved yet. This guide breaks down its triple-hormone mechanism, compares it to semaglutide and tirzepatide, and warns of black market risks. Learn why experts urge caution.
4 min read
Wegovy Oral Tablet Lands in US, Delivering Innovative Pill-Based Solution for Weight Management
The United States now offers an additional avenue for weight reduction as Novo Nordisk introduces its Wegovy oral medication across the country. This daily tablet, featuring semaglutide, represents the initial and sole GLP-1 pill for adults, simplifying obesity management without injections. Clinical studies indicate notable weight loss, though side effects may occur.
2 min read
NHS Caution on Mounjaro as Thousands Get 'Key Notice' About Shots
As new health goals emerge in January, weight loss medications like Mounjaro gain popularity, but an NHS notice warns about potential interactions with birth control and hormone therapy. Estimates indicate hundreds of thousands are using these drugs privately, with guidelines stressing extra precautions for absorption issues.
4 min read
What is the price of tirzepatide for shedding pounds with and without coverage?
Tirzepatide, known as Mounjaro or Zepbound, serves as a medication for diabetes and weight management but comes with a steep price. Without insurance, monthly expenses can range from $500 to $1,900, varying by type and purchase location. This piece explores pricing details, insurance coverage, cost-saving strategies, and budget-friendly substitutes.
8 min read
Lilly Seeks FDA OK for Orforglipron, an Oral Weight Loss Drug | TechTarget
Eli Lilly has submitted orforglipron, its oral GLP-1 therapy, for FDA approval following successful phase 3 trial outcomes. The weight loss pill demonstrates promise in addressing weight regain issues often seen when patients discontinue GLP-1 therapy. The study showed patients maintained weight loss for up to a year.
3 min read
The Next Generation of Ozempic: Exploring the Future of Weight Loss
Blockbuster weight-loss shots are evolving, with new treatments in development that aim to improve upon current injections. Drugmakers are developing a new wave of GLP-1 treatments, with several promising candidates in the pipeline. These experimental treatments aim to address some of the biggest gripes about today's injections.
4 min read
Indian Drugmakers Adjust GLP-1 Pricing as Novo Nordisk Reduces Wegovy Cost in India
Indian drugmakers are modifying their pricing strategies for weight-loss injections after Novo Nordisk decreased the price of Wegovy. Generic companies are now reassessing their launch prices due to this shift. Competition is anticipated to lower prices in the GLP-1 market.
3 min read
Doctor Issues Warning About Overlooked Mounjaro Side Effect
Weight loss injections, initially for diabetes, are now popular for rapid weight loss. However, a doctor reports an increase in hemorrhoid cases among patients using drugs like Mounjaro and Ozempic, citing significant bowel changes and increased straining during exercise.
4 min read
Eli Lilly Advances Amylin Obesity Drug to Late-Stage Trials After Study Shows 20% Weight Reduction
Eli Lilly is set to begin late-stage trials for its investigational amylin obesity drug following promising mid-stage study results. The trial showed the highest dose of the weekly injection, eloralintide, resulted in an average weight loss of 20.1% in obese or overweight patients over 48 weeks.
3 min read